The significant beat on earnings growth and raised EPS guidance suggest strong execution and successful integration of the Nevro acquisition. Traders should monitor whether the elevated growth rates (particularly the 25.7% YoY revenue growth) can be sustained in 2026, and watch for margin expansion as the company scales. The reaffirmed revenue guidance indicates management sees continued momentum.
Price Chart
Executive Summary
Globus Medical reported strong fourth quarter and full-year 2025 results with worldwide net sales of $826.4 million (up 25.7% YoY) and full-year sales of $2.94 billion (up 16.7% YoY). GAAP diluted EPS surged 442.6% to $1.03 in Q4 and 425.4% to $3.92 for the year. The company reaffirmed 2026 revenue guidance of $3.18-$3.22 billion and raised non-GAAP EPS guidance to $4.40-$4.50, reflecting confidence in continued growth driven by the Nevro acquisition integration and base business performance.
Key Financial Metrics
Key Facts
- Q4 2025 worldwide net sales: $826.4 million, up 25.7% YoY (24.7% constant currency)
- Full-year 2025 net sales: $2.94 billion, up 16.7% YoY (16.2% constant currency)
- Q4 GAAP diluted EPS: $1.03, up 442.6% YoY; full-year: $3.92, up 425.4% YoY
- Non-GAAP diluted EPS: $1.28 in Q4 (up 52.1% YoY), $3.98 for full-year (up 30.8% YoY)
- Nevro acquisition contributed $99.7 million in Q4 sales
- Base business (excluding Nevro) grew 10.6% in Q4 and 5.0% for full-year
- 2026 guidance: revenue $3.18-$3.22 billion (reaffirmed), non-GAAP EPS raised to $4.40-$4.50 (from $4.30-$4.40)
- U.S. sales grew 27.5% in Q4 and 18.4% for full-year; international grew 19.0% in Q4 and 10.0% full-year
Financial Impact
Revenue growth of 25.7% in Q4 and 16.7% for full-year 2025, with non-GAAP EPS guidance raised by $0.10 at midpoint
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Base business (excluding Nevro) | $2.6B | +5.0% |
| Nevro acquisition | $293.6M | — |
Risk Factors
- High growth rate may be partially acquisition-driven (Nevro contributed $99.7M in Q4 sales), raising sustainability questions
- Base business growth (10.6% in Q4, 5.0% full-year) is solid but less impressive than headline numbers
- Future performance dependent on successful integration of recent acquisitions and new product launches
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 11 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (GMED) — Batch item 1 | 0001628280-26-011124 |
| Document: gmed-20260224.htm | 0001628280-26-011124 |
| Document: 0001628280-26-011124-index-headers.html | 0001628280-26-011124 |
| Document: 0001628280-26-011124-index.html | 0001628280-26-011124 |
| Document: 0001628280-26-011124.txt | 0001628280-26-011124 |
| 8-K Filing (GMED) — Batch item 6 | 0001628280-26-011124 |
| Document: gmed-20260224.htm | 0001628280-26-011124 |
| Document: 0001628280-26-011124-index-headers.html | 0001628280-26-011124 |
| Document: 0001628280-26-011124-index.html | 0001628280-26-011124 |
| Document: 0001628280-26-011124.txt | 0001628280-26-011124 |
| CONTEXT: Previous Earnings (2026-02-24) | 0001628280-26-011124 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Institutional Cluster | $81.66 | awaiting T+20 | — | $81.41 (−0.31%) |
Sep 15, 2026 5w ago | 144 | $74.69 $76.32 | ▲ +2.18% | ▼ −0.80% | $81.41 (+9.00%) |
Sep 11, 2026 6w ago | Court Ruling | $75.77 $76.24 | ▲ +0.62% | ▼ −1.64% | $81.41 (+7.44%) |
Aug 26, 2026 8w ago | Press Release | $82.54 $74.16 | ▼ −10.15% | ▼ −10.05% | $81.41 (−1.37%) |
Jul 16, 2026 14w ago | Press Release | $77.00 $85.90 | ▲ +11.56% | ▲ +7.11% | $81.41 (+5.73%) |
Jun 4, 2026 20w ago | 8-K | $80.00 $80.50 | ▲ +0.63% | ▼ −1.24% | $81.41 (+1.76%) |
Jun 4, 2026 20w ago | Court Ruling | $80.00 $80.12 | ▼ −0.15% | ▼ −1.52% | $81.41 (−1.76%) |
Apr 24, 2026 26w ago | DEFA14A | $93.70 $85.10 | ▼ −9.18% | ▼ −14.13% | $81.41 (−13.12%) |
Feb 24, 2026 34w ago | 8-K | $96.22 $87.35 | ▼ −9.22% | ▼ −3.98% | $81.41 (−15.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers